# OnCo record lymphoma-living-hodgkin-survivorship-screening (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "lymphoma-living-hodgkin-survivorship-screening" ;
  schema:name "After Hodgkin lymphoma: the late effects, and the screening that follows them"@en ;
  schema:alternateName "Hodgkin survivorship screening"@en, "Breast screening after chest radiotherapy"@en, "Late effects clinic Hodgkin"@en ;
  schema:description "Most people treated for Hodgkin lymphoma are cured, and the long follow-up cohorts show that the treatment leaves a raised risk of heart disease, of a second cancer and of an underactive thyroid for decades. Several of those risks have a screening programme attached, and the commonest failure is not being enrolled in it."@en ;
  schema:url <https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1505949>, <https://doi.org/10.1001/jamainternmed.2015.1180>, <https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols/protocols-for-surveillance-of-women-at-higher-risk-of-developing-breast-cancer>, <https://lymphoma-action.org.uk/news/annual-breast-screening-missed-following-radiotherapy-hodgkin-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://www.cancerresearchuk.org/about-cancer/hodgkin-lymphoma/living-with> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/technologies/mri/> ;
  onco:terms <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/terms/lymphoma-living-scanxiety-and-surveillance/> .